Literature DB >> 34322296

Incidence of lupus anticoagulant in hospitalized covid-19 patients.

Tarek Owaidah1,2, Mahasen Saleh3, Amelita M Aguilos1, Abdulllah Al Amri1, Khalid Maghrabi4, Mustafa Owaidah2, Khawar Siddiqui3, Khalid Alsaleh5, Randa Alnounou1.   

Abstract

BACKGROUND: Procoagulant profile of 2019-nCoV/SARS-CoV-2 has been well documented over the last year. Perturbance in coagulating factors has also been reported in Covid-19 patients, including increased d-dimers and reports of lupus anticoagulant (LA).
METHODS: The current study aimed to identify the incidence of positivity of lupus anticoagulant in Covid-19 patients and analyze the association between LA and D-dimer in predicting thrombosis and mortality in one-hundred and five hospitalized adult (age >14 years) patients and forty-three hospitalized pediatric (age <14 years) patients with a confirmed diagnosis of Covid-19 between June 2020 and September 2020.
RESULTS: Twenty-one (20%) adult patients were tested positive for PTT LA, of which nine (8.6%) turned out to be confirmed positive for LA through StaClot and DRVVT Ratio tests. Six (14%) pediatric patients were positive for PTT LA, and only one (2.3%) had positive StaClot. Median D-dimer at admission was positively correlated with age and CRP among adult patients and was significantly higher in expired cases (P=0.001). No association between any of the coagulation tests and thrombosis or mortality was observed in the pediatric cohort.
CONCLUSION: We report an increased incidence of LA in Covid-19 patients, yet we didn't find any association between thrombotic events or mortality, probably due to the small sample size. AJBR
Copyright © 2021.

Entities:  

Keywords:  Covid-19; D-dimers; lupus anti-coagulant; thrombosis

Year:  2021        PMID: 34322296      PMCID: PMC8303017     

Source DB:  PubMed          Journal:  Am J Blood Res        ISSN: 2160-1992


  20 in total

Review 1.  Pathophysiology and treatment of coagulopathy in massive hemorrhage and hemodilution.

Authors:  Daniel Bolliger; Klaus Görlinger; Kenichi A Tanaka
Journal:  Anesthesiology       Date:  2010-11       Impact factor: 7.892

2.  Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis: Update of the guidelines for lupus anticoagulant detection and interpretation.

Authors:  Katrien M J Devreese; Philip G de Groot; Bas de Laat; Doruk Erkan; Emmanuel J Favaloro; Ian Mackie; Marta Martinuzzo; Thomas L Ortel; Vittorio Pengo; Jacob H Rand; Armando Tripodi; Denis Wahl; Hannah Cohen
Journal:  J Thromb Haemost       Date:  2020-11       Impact factor: 5.824

3.  Profile of natural anticoagulant, coagulant factor and anti-phospholipid antibody in critically ill COVID-19 patients.

Authors:  Yan Zhang; Wei Cao; Wei Jiang; Meng Xiao; Yongzhe Li; Ning Tang; Zhengyin Liu; Xiaowei Yan; Yongqiang Zhao; Taisheng Li; Tienan Zhu
Journal:  J Thromb Thrombolysis       Date:  2020-10       Impact factor: 2.300

4.  Lupus anticoagulant is frequent in patients with Covid-19: Response to Reply.

Authors:  Inès Harzallah; Agathe Debliquis; Bernard Drénou
Journal:  J Thromb Haemost       Date:  2020-06-30       Impact factor: 5.824

5.  Are antiphospholipid antibodies associated with thrombotic complications in critically ill COVID-19 patients?

Authors:  Virginie Siguret; Sebastian Voicu; Marie Neuwirth; Maxime Delrue; Etienne Gayat; Alain Stépanian; Bruno Mégarbane
Journal:  Thromb Res       Date:  2020-07-08       Impact factor: 3.944

6.  Lupus Anticoagulant and Abnormal Coagulation Tests in Patients with Covid-19.

Authors:  Louise Bowles; Sean Platton; Nada Yartey; Minal Dave; Kurtis Lee; Daniel P Hart; Vickie MacDonald; Laura Green; Suthesh Sivapalaratnam; K John Pasi; Peter MacCallum
Journal:  N Engl J Med       Date:  2020-05-05       Impact factor: 91.245

7.  Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia.

Authors:  Ning Tang; Dengju Li; Xiong Wang; Ziyong Sun
Journal:  J Thromb Haemost       Date:  2020-03-13       Impact factor: 5.824

8.  High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study.

Authors:  Julie Helms; Charles Tacquard; François Severac; Ian Leonard-Lorant; Mickaël Ohana; Xavier Delabranche; Hamid Merdji; Raphaël Clere-Jehl; Malika Schenck; Florence Fagot Gandet; Samira Fafi-Kremer; Vincent Castelain; Francis Schneider; Lélia Grunebaum; Eduardo Anglés-Cano; Laurent Sattler; Paul-Michel Mertes; Ferhat Meziani
Journal:  Intensive Care Med       Date:  2020-05-04       Impact factor: 17.440

9.  High prevalence of antinuclear antibodies and lupus anticoagulant in patients hospitalized for SARS-CoV2 pneumonia.

Authors:  Carmine Gazzaruso; Nicoletta Carlo Stella; Giuseppe Mariani; Carlo Nai; Adriana Coppola; Daniela Naldani; Pietro Gallotti
Journal:  Clin Rheumatol       Date:  2020-05-27       Impact factor: 2.980

10.  Antiphospholipid antibodies in patients with COVID-19: A relevant observation?

Authors:  Katrien M J Devreese; Eleni A Linskens; Dominique Benoit; Harlinde Peperstraete
Journal:  J Thromb Haemost       Date:  2020-07-23       Impact factor: 16.036

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.